Neumora Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.1%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.92next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| NMRA-511 MAD Cohort Data in Healthy Elderly Volunteers | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash Runway QuarterlyQ3 2027Target: Q3 2027
Workforce Reduction Progress Quarterly35.0Target: 35% reduction completed
Annualized Cost Savings Annually10MTarget: $10 million annualized savings
Watch Items
- NMRA-511 Phase 2b Dose Ranging Study InitiationTrigger: Initiation by end of 2026Action: Monitor clinical trial registry updates and company press releases for study start.
- NMRA-898 Phase 1 Schizophrenia Data ReadoutTrigger: Data release in H2 2026Action: Evaluate safety, tolerability, and pharmacokinetic profile of the M4 PAM candidate.
- NMRA-215 Obesity Program Clinical EntryTrigger: Clinical study initiation by year-end 2026Action: Verify completion of the repeat 13-week rat toxicology study in mid-2026 and subsequent IND filing.
Research as of 20 Jun 2026